Skip to main content

SYLOGIST Reports Second Quarter 2025 Results

Strong Bookings and continuing SaaS Revenue growth Q2 2025 Highlights 1  Revenue (in $ millions)  SaaS Subscription Recurring TotalReported Y/Y growth Reported Y/Y growth Reported Y/Y growth$7.9 13.1% $10.9 4.0% $15.7 (6.9)% SaaS ARR up 12.5% Y/Y to $31.7 million; Total ARR up 3% Y/Y to $43.8 million; SaaS NRR of 107%; Bookings up 33% Y/Y to 17.1 million; Adjusted EBITDA margin of 15.3% or $2.4 million; Gross profit margin of 58%; and Recurring Revenue at 70% of Total Revenue.CALGARY, Alberta, Aug. 14, 2025 (GLOBE NEWSWIRE) — Sylogist Ltd. (TSX: SYZ) (“Sylogist” or the “Company”), a leading public sector SaaS company, today announced its results for the second quarter of fiscal 2025, ended June 30, 2025. “I am very pleased with our Q2 performance,” said Bill Wood, CEO of Sylogist. “In...

Continue reading

FitLife Brands Announces Second Quarter 2025 Results

OMAHA, NE, Aug. 14, 2025 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the second quarter ended June 30, 2025. Highlights for the second quarter ended June 30, 2025 include:Total revenue was $16.1 million, 5% lower than the second quarter of 2024.   Online revenue was $10.4 million, representing 65% of total revenue and down 7% compared to the second quarter of 2024. Gross margin was 42.8% compared to 44.8% during the second quarter of 2024. Net income for the second quarter of 2025 was $1.7 million compared to $2.6 million during the same period last year, with merger and acquisition related expense associated with the Irwin Naturals transaction accounting for most...

Continue reading

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

– Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC) – OLC pivotal study data, published in the Clinical Journal of the American Society of Nephrology (CJASN), demonstrated OLC was well tolerated and enabled serum phosphate control in over 90% of patients with a low pill burden – Ended Q2 with $22.3 million of cash with expected runway into the second half of 2026 LOS ALTOS, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended June 30, 2025, and provided a business update. “Our team has...

Continue reading

atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinicReported positive topline data from the core, blinded stage of the Phase 2b clinical trial of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD) BPL-003 met its primary and all key secondary endpoints, and demonstrated rapid, robust and durable antidepressant effects for up to 8 weeks with a single dose Topline data from the eight-week open-label extension stage of the Phase 2b clinical trial of BPL-003 is expected in the third quarter of 2025 On track to submit End-of-Phase 2 meeting request to the U.S. Food and Drug Administration (FDA) in the third quarter of 2025 Cash, cash equivalents, short-term securities,...

Continue reading

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025 On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the quarter ended June 30, 2025, and provided a corporate update...

Continue reading

Newton Golf Company Reports Second Quarter 2025 Financial Results

Revenue Climbs 154% Year-over-Year as Tour Adoption and Product Momentum Accelerate CAMARILLO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — via IBN – Newton Golf Company (NASDAQ: NWTG) (“Newton Golf” or the “Company”), a technology-forward golf company delivering physics-based performance innovations, today announced financial results for the second quarter ended June 30, 2025. Second Quarter and Year-to-Date 2025 HighlightsQ2 2025: Revenue increased 154% year-over-year to $2.1 million, compared to $813,000 in Q2 2024 First Six Months 2025: Revenue increased 182% year-over-year to $3.3 million, compared to $1.2 million in the first half of 2024 Q2 2025: Gross profit rose 186% to $1.4 million, up from $489,000 in Q2 2024 First Six Months 2025: Gross profit increased 224% to $2.3 million, up from $695,000 in...

Continue reading

reAlpha Tech Corp. Announces 1,909% Year-over-Year Revenue Growth for Quarter Ended June 30, 2025

DUBLIN, Ohio, Aug. 14, 2025 (GLOBE NEWSWIRE) — reAlpha Tech Corp. (Nasdaq: AIRE) (the “Company” or “reAlpha”), an AI-powered real estate technology company, today announced financial results and business highlights for the quarter ended June 30, 2025. Financial HighlightsRevenue increased 1,909% to approximately $1.3 million in the second quarter of 2025, compared to $62,353 in the second quarter of 2024. Cash at the end of the second quarter of 2025 was $587,311 compared to approximately $3.7 million in the second quarter of 2024. Gross profit was $621,465 in the second quarter of 2025, compared to $44,103 in the second quarter of 2024. The increase was primarily driven by mortgage brokerage transactions provided by our subsidiaries, reAlpha Mortgage (f/k/a Be My Neighbor) and GTG Financial, Inc., which included loan origination...

Continue reading

Xunlei Announces Unaudited Financial Results for the Second Quarter Ended June 30, 2025

SHENZHEN, China, Aug. 14, 2025 (GLOBE NEWSWIRE) — Xunlei Limited (“Xunlei” or the “Company”) (Nasdaq: XNET), a leading technology company providing distributed cloud services in China, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights:Total revenues were US$104.0 million, representing an increase of 30.6% year-over-year.  Subscription revenues were US$36.4 million, representing an increase of 10.5% year-over-year.  Live-streaming and other services revenues were US$37.6 million, representing an increase of 85.5% year-over-year.  Cloud computing revenues were US$30.0 million, representing an increase of 13.6% year-over-year.  Gross profit was US$51.2 million, representing an increase of 25.9% year-over-year, and gross profit...

Continue reading

Pro Kapital Council approved Consolidated Interim Report for II Quarter and 6 Months of 2025 (Unaudited)

MANAGEMENT REPORT Real Estate Development Tallinn By the second quarter of 2025, construction of the final phase of the Kalaranna development (4 buildings, 146 units) reached an end with some landscaping and a few client modifications works remaining. As of the publication of this report, 76 sold apartments have been handed over to buyers, and the overall sales rate has reached 60.7%. In Kristiine City, we are continuing the design and building permit process for four different projects submitted to the Tallinn City Planning Department:“Dunte” – still awaiting the issuance of the building permit. Sammu 2/4 / Sõjakooli 15 – building permit application was submitted in December 2024. Marsi 1 / Sõjakooli 13 – building permit application was submitted in February 2025. Sammu 3 / Sõjakooli 17 – we are in...

Continue reading

Pro Kapital Council approved Consolidated Interim Report for II Quarter and 6 Months of 2025 (Unaudited)

MANAGEMENT REPORT Real Estate Development Tallinn By the second quarter of 2025, construction of the final phase of the Kalaranna development (4 buildings, 146 units) reached an end with some landscaping and a few client modifications works remaining. As of the publication of this report, 76 sold apartments have been handed over to buyers, and the overall sales rate has reached 60.7%. In Kristiine City, we are continuing the design and building permit process for four different projects submitted to the Tallinn City Planning Department:“Dunte” – still awaiting the issuance of the building permit. Sammu 2/4 / Sõjakooli 15 – building permit application was submitted in December 2024. Marsi 1 / Sõjakooli 13 – building permit application was submitted in February 2025. Sammu 3 / Sõjakooli 17 – we are in...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.